Management of Hepatitis C Virus in the Transplant Patient

Clinics in Liver Disease

Volumn 11, Issue 2, 2007, Pages 355-376

  Berenguer, Marina ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ANGIOTENSIN ANTAGONIST; ANTIVIRUS AGENT; CALCINEURIN INHIBITOR; CIVACIR; CORTICOSTEROID; IMMUNOGLOBULIN; INTERFERON; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON; PEGINTERFERON ALPHA2A; PLACEBO; RAPAMYCIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN; STEROID; UNCLASSIFIED DRUG;

ANEMIA; ANTIVIRAL THERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; GRAFT REJECTION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CIRRHOSIS; LIVER GRAFT; LIVER TRANSPLANTATION; LOW DRUG DOSE; MONOTHERAPY; NEUTROPENIA; ORGAN DONOR; RANDOMIZED CONTROLLED TRIAL; RECURRENT INFECTION; RETRANSPLANTATION; REVIEW; UNSPECIFIED SIDE EFFECT;

ANTIVIRAL AGENTS; HEPATITIS C; HUMANS; IMMUNOLOGIC FACTORS; LIVER TRANSPLANTATION;

EID: 34347227099     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2007.04.010     Document Type: Review

References (82)

1. Berenguer M. Hepatitis C and Liver transplantation. Current Opinion Organ Transplantation 10 (2005) 81-89
2. Samuel D., Forns X., Berenguer M., et al. Report of the Monothematic EASL Conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006). J Hepatol 45 1 (2006) 127-143
3. El-Serag H.B. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 127 (2004) S27-S34
4. Berenguer M., Lopez-Labrador F.X., and Wright T.L. Hepatitis C and liver transplantation. J Hepatol 35 (2001) 666-678
5. Wiesner R.H., Sorrell M., and Villamil F. Report of the First International Liver Transplant Society Consensus Conference on liver transplantation and hepatitis C. Liver Transpl 9 Suppl 3 (2003) S1-S9
6. Gane E. The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transpl 9 Suppl 3 (2003) S28-S34
7. Berenguer M., Prieto M., San Juan F., et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 36 (2002) 202-210
8. Neumann U.P., Berg T., Bahra M., et al. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. Transplantation 77 (2004) 226-231
9. Forman L.M., Dewis J.D., Berlin J.A., et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 122 4 (2002) 889-896
10. Berenguer M. Treatment of hepatitis C after liver transplantation. Clin Liver Dis 9 4 (2005) 579-600
11. Neumann U.P., Berg T., Bahra M., et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 41 (2004) 830-836
12. Berenguer M., Aguilera V., Prieto M., et al. Delayed onset of severe hepatitis C-related liver damage following liver transplantation: a matter of concern?. Liver Transpl 9 (2003) 1152-1158
13. Berenguer M. What determines the natural history of recurrent hepatitis C after liver transplantation. J Hepatol 42 4 (2005) 448-456
14. Firpi R.J., Abdelmalek M.F., Soldevila-Pico C., et al. One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transpl 10 (2004) 1240-1247
15. Blasco A., Forns X., Carrión J.A., et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology 43 3 (2006) 492-499
16. Benlloch S., Berenguer M., Aguilera V., et al. Prediction of fibrosis in HCV-infected liver transplant recipients with a simple non-invasive index. Liver Transpl 11 4 (2005) 456-462
17. Carrion JA, Navasa M, Bosch J, et al. Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation. Liver Transpl 2006;12(12):1791-8.
18. McCaughan G.W., and Zekry A. Mechanisms of HCV reinfection and allograft damage after liver transplantation. J Hepatol 40 (2004) 368-374
19. Berenguer M., Prieto M., Rayón J.M., et al. Natural history of clinically compensated HCV-related graft cirrhosis following liver transplantation. Hepatology 32 (2000) 852-858
20. Berenguer M., Crippin J., Gish R., et al. A model to predict severe HCV-related disease following liver transplantation. Hepatology 38 (2003) 34-41
21. Burak K.W., Kremers W.K., Batts K.P., et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 8 (2002) 362-369
22. Wali M., Harrison R.F., Gow P.J., et al. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 51 (2002) 248-252
23. Samonakis D.N., Triantos C.K., Thalheimer U., et al. Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation. Liver Transpl 11 4 (2005) 384-385
24. Lake J.R. The role of immunosuppression in recurrence of hepatitis C. Liver Transpl 9 (2003) S63-S66
25. Watt K.D., Lyden E.R., Gulizia J.M., et al. Recurrent hepatitis C posttransplant: early preservation injury may predict poor outcome. Liver Transpl 12 1 (2006) 134-139
26. Foxton MR, Quaglia A, Muiesan P, et al. The impact of diabetes mellitus on fibrosis progression in patients transplanted for hepatitis C. Am J Transplant 2006;6(8):1922-9.
27. Rosen H.R. Retransplantation for hepatitis C: implications of different policies. Liver Transpl 6 (2000) S41-S46
28. Berenguer M., Aguilera V., Prieto M., et al. Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients. Liver Transpl 12 5 (2006) 762-767
29. Martin P., Busuttil R.W., Goldstein R.M., et al. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis C: a prospective randomized trial. Liver Transpl 10 (2004) 1258-1262
30. Berenguer M. Live donor liver transplantation for hepatitis C: new data, old story. Liver Transpl 12 4 (2006) 516-519
31. Gawrieh S., Papouchado B.G., Burgart L.J., et al. Early hepatic stellate cell activation predicts severe hepatitis C recurrence after liver transplantation. Liver Transpl 11 10 (2005) 1207-1213
32. Rimola A., Londoño M.C., Guevara G., et al. Beneficial effect of angiotensin-blocking agents on graft fibrosis in hepatitis C recurrence after liver transplantation. Transplantation 78 (2004) 686-691
33. Tisone G., Orlando G., Cardillo A., et al. Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence. J Hepatol 44 4 (2006) 702-709
34. Berenguer M., Aguilera V., Prieto M., et al. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. J Hepatol 44 4 (2006) 717-722
35. Terrault N.A. Prophylactic and preemptive therapies for thepatitis C virus infected patients undergoing liver transplantation. Liver Transpl 9 (2003) S95-S100
36. Davis G.L., Nelson D.R., Terrault N., et al. A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transpl 11 (2005) 941-949
37. Everson G.T. Should we treat patients with chronic hepatitis C on the waiting list?. J Hepatol 42 (2005) 456-462
38. Crippin J.S., Sheiner P., Terrault N.A., et al. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 8 (2002) 350-355
39. Forns X., Garcia-Retortillo M., Serrano T., et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 39 (2003) 389-396
40. Thomas R.M., Brenns J.J., Guzmán-Hartman G., et al. Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl 9 (2003) 905-915
41. Everson G.T., Trotter J., Forman L., et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 42 2 (2005) 255-262
42. Bizollon T., Admed S.N.S., Radenne S., et al. Long-term histologic improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplant patients with hepatitis C recurrence. Gut 52 (2003) 283-287
43. Abdelmalek M.F., Firpi R.J., Soldevila-Pico C., et al. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transpl 10 (2004) 199-207
44. Garcia-Retortillo M., Forns X., Feliu A., et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 35 (2002) 680-687
45. Castells L., Vargas V., Allende H., et al. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol 43 1 (2005) 53-59
46. Chalasani N., Manzarbeitia C., Ferenci P., et al. Peginterferon alfa 2a for recurrence of hepatitis C after liver transplantation: two randomised, controlled trials. Hepatology 41 2 (2005) 289-298
47. Sugawara Y., Makuuchi M., Matsui Y., et al. Preemptive therapy for hepatitis C virus after living-donor liver transplantation. Transplantation 78 9 (2004) 1308-1311
48. Shergill A.K., Khalili M., Straley S., et al. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C infected patients undergoing liver transplantation. Am J Transplant 5 (2005) 118-124
49. Jain A.B., Eghtesad B., Venkataramanan R., et al. Ribavirin dose modification based on renal function is necessary to reduce hemolysis in liver transplant patients with hepatitis C virus infection. Liver transpl 8 (2002) 1007-1013
50. Lavezzo B., Franchello A., Smedile A., et al. Treatment of recurrent hepatitis C in liver transplants: efficacy of a six versus twelve month course of interferon alfa 2b with ribavirin. J Hepatol 37 (2002) 247-252
51. Samuel D., Bizollon T., Feray C., et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 124 (2003) 642-650
52. Ross A.S., Bhan A.K., Pascual M., et al. Pegylated interferon alfa-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C. Clin Transpl 18 (2004) 166-173
53. Dumortier J., Scoaxec J.Y., Chevallier P., et al. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa 2b and ribavirin combination. J Hepatol 40 (2004) 669-674
54. Rodríguez-Luna H., Khatib A., Sharma P., et al. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alfa 2b and ribavirin: an open label series. Transplantation 77 (2004) 190-194
55. Neff G.W., Montalbano M., O'Brien C., et al. Treatment of established recurrent hepatitis C in liver transplant recipients with pegylated interferon alfa-2b and ribavirin therapy. Transpl 78 (2004) 1303-1307
56. Toniutto P., Fabris C., Fumo E., et al. Pegylated versus standard interferon-alpha in antiviral regimens for post-transplant recurrent hepatitis C: comparison of tolerability and efficacy. J Gastroenterol Hepatol 20 4 (2005) 577-582
57. Babatin M., Schindel L., and Burak K.W. Pegylated-interferon alpha 2b and ribavirin for recurrent hepatitis C after liver transplantation: from a Canadian experience to recommendations for therapy. Can J Gastroenterol 19 6 (2005) 359-365
58. Biselli M., Andreone P., Gramenzi A., et al. Pegylated interferon plus ribavirin for recurrent Hepatitis C infection after liver transplantation in naive and non-responder patients on a stable immunosuppressive regimen. Dig Liver Dis 38 1 (2006) 27-32
59. Berenguer M., Palau A., Fernandez A., et al. Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transpl 12 7 (2006) 1067-1076
60. Oton E., Barcena R., Moreno-Planas J.M., et al. Hepatitis C recurrence after liver transplantation: viral and histologic response to full-dose PEG-interferon and ribavirin. Am J Transplant 6 10 (2006) 2348-2355
61. Sulkowski M.S. Management of the hematologic complications of hepatitis C therapy. Clin Liver Dis 9 4 (2005) 601-616 vi
62. Curry M.P., and Afdhal N.H. Use of growth factors with antiviral therapy for chronic hepatitis C. Clin Liver Dis 9 3 (2005) 439-451 vii
63. Todd-Stravitz R., Shiffman M.L., Sanyal A.J., et al. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation. Liver Transpl 10 (2004) 850-858
64. Saab S., Kalmaz D., Gajjar N.A., et al. Outcomes of acute rejection after interferon therapy in liver transplant recipients. Liver transpl 10 (2004) 859-867
65. Gopal D.V., and Rosen H.R. Duration of antiviral therapy for cholestatic HCV recurrence may need to be indefinite. Liver Transpl 9 (2003) 348-353
66. Rosen H.R., Prieto M., Casanovas-Taltavull T., et al. Validation and refinement of survival models for liver retransplantation. Hepatology 38 (2003) 460-469
67. Carmiel-Haggai M., Fiel M.I., Gaddipati H.C., et al. Recurrent hepatitis C after retransplantation: factors affecting graft and patient outcome. Liver Transpl 11 (2005) 1567-1573
68. Bizollon T., Palazzo U., Ducerf C., et al. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology 26 (1997) 500-504
69. De Vera M.E., Smallwood G.A., Rosado K., et al. Interferon-alpha and ribavirin for the treatment of recurrent hepatitis C after liver transplantation. Transplantation 71 (2001) 678-686
70. Kornberg A., Hommann M., Tannapfel A., et al. Long-term combination of interferon alfa-2b and ribavirin for hepatitis C recurrence in liver transplant patients. Am J transpl 1 (2001) 350-355
71. Alberti A.B., Belli L.S., Airoldi A., et al. Combined therapy with interferon and low-dose ribavirin in posttransplantation recurrent hepatitis C: a pragmatic study. Liver Transpl 7 (2001) 870-876
72. Firpi R.J., Abdelmalek M.F., Soldevila-Pico C., et al. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transpl 8 (2002) 1000-1006
73. Gopal D.V., Rabkin J.M., Berk B.S., et al. Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin. Liver Transpl 7 (2001) 181-190
74. Ahmad J., Dodson S.F., Demetris A.J., et al. Recurrent hepatitis C after liver transplantation: a nonrandomized trial of interferon alfa alone versus interferon alfa and ribavirin. Liver Transpl 7 (2001) 863-869
75. Narayanan M., Poterucha J.J., El-Amin O.M., et al. Treatment of posttransplantation recurrence of hepatitis C wih interferon and ribavirin: lessons on tolerability and efficacy. Liver Transpl 8 (2002) 623-629
76. Shakil A.O., McGuire B., Crippin J., et al. A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C. Hepatology 36 (2002) 1253-1258
77. Giostra E., Kullak-Ublick G.A., Keller W., et al. Ribavirin/interferon-alfa sequential treatment of recurrent hepatitis C after liver transplantation. Transpl Int 17 (2004) 169-176
78. Berenguer M., Prieto M., Palau A., et al. Recurrent hepatitis C genotype 1b following liver transplantation (OLT): treatment with combination interferon-ribavirin therapy (CT). Eur J Gastro Hepatol 16 11 (2004) 1207-1212
79. Mukherjee S., Gilroy R.K., McCashland T.M., et al. Pegylated interferon for recurrent hepatitis C in liver transplant recipients with renal failure: a prospective cohort study. Transpl Proc 35 (2003) 1478-1479
80. Sheiner P., Boros P., Klion F.M., et al. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology 28 (1998) 831-838
81. Singh N., Gayowski T., Wannstedt C., et al. Interferon-a for prophylaxis of recurrent viral hepatitis C in liver transplant recipients. Transplantation 65 (1998) 82-86
82. Mazzaferro V., Tagger A., Schiavo M., et al. Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment. Transpl Proc 33 (2001) 1355-1357